PIK3CD and cancer: In summary, compared with MAPK pathway inhibitors, monotherapy or combination therapy with PI3K pathway inhibitors has limited benefits for patients with KRAS-mutated cancers, although such PI3K inhibitors may reverse resistance to KRAS-G12C inhibitors (discussed later).